Comparative Pharmacology
Head-to-head clinical analysis: SODIUM SULFACETAMIDE versus SULFAMYLON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SODIUM SULFACETAMIDE versus SULFAMYLON.
SODIUM SULFACETAMIDE vs SULFAMYLON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfacetamide is a sulfonamide antibiotic that inhibits bacterial dihydropteroate synthase, thereby blocking the synthesis of folic acid and ultimately nucleic acid synthesis, leading to bacteriostatic activity.
Sulfamylon (mafenide acetate) is a synthetic sulfonamide that exerts bacteriostatic activity against a wide range of Gram-negative and Gram-positive organisms. It acts by inhibiting the enzyme dihydropteroate synthase, which is involved in folate synthesis, thereby blocking bacterial DNA replication. Additionally, it may be bactericidal at high concentrations via inhibition of cell wall synthesis.
1-2 drops of 10% or 30% solution into conjunctival sac every 2-3 hours during waking hours for 7-10 days.
Topical: Apply a thin layer to the wound once or twice daily. Maximum coverage area should not exceed body surface area of 20%.
None Documented
None Documented
7-12 hours in normal renal function; prolonged to 20-50 hours in renal impairment.
The terminal elimination half-life is approximately 7-8 hours in patients with normal renal function. In renal impairment, half-life may be prolonged, requiring dosing adjustments.
Renal: 85-100% unchanged drug via glomerular filtration and tubular secretion. Biliary/fecal: <5%.
Primarily renal excretion as unchanged drug and its metabolite; approximately 87% of a dose is recovered in urine within 24 hours as sulfacetamide and its deacetylated metabolite, with about 10% as unchanged drug. Less than 2% is excreted in feces.
Category A/B
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic